SIR 2024
Portal Hypertension
Juil Park, MD
Assistant Professor
Severance Hospital, Republic of Korea
Disclosure information not submitted.
Man-Deuk Kim, MD,PhD,FSIR
Chief of Vascular and Interventional Radiology
Severance Hospital, Yonsei University College of Medicine, Republic of Korea
Financial relationships: Full list of relationships is listed on the CME information page.
Jong Yun Won, MD, PhD
Professor
Yonsei University College of Medicine, Severance H, Republic of Korea
Disclosure information not submitted.
Gyoung Min Kim, MD, PhD
Assistant Professor
Yonsei University Severance Hospital, Republic of Korea
Disclosure information not submitted.
Kichang Han, MD, PhD
Associate Professor
Severance Hospital, Yonsei University, College of Medicine, Republic of Korea
Financial relationships: Full list of relationships is listed on the CME information page.
Joon Ho Kwon, MD
Clinical assistant professor
Severance hospital, Republic of Korea
Disclosure information not submitted.
Sungmo Moon, MD
Professor
Severance hospital, Republic of Korea
Disclosure information not submitted.
Hyung Cheol Kim, MD
Clinical assistant professor
Severance hospital, Republic of Korea
Disclosure information not submitted.
To evaluate the efficacy and safety of stent graft placement for portal vein occlusion due to periampullary malignancies
Materials and Methods:
This retrospective single-center study included 58 patients (36 men and 22 women; mean ± SD age, 64.2 ± 9.1 years) who underwent percutaneous transhepatic portal vein stent (n = 45) or stent graft (n = 13) placement for portal vein occlusion due to periampullary malignancies (38 cases of pancreas cancer and 20 cases of biliary cancer). from January 2018 to December 2022. These patients were referred to interventional radiology for portal hypertension-related symptoms such as refractory ascites (n = 36), variceal bleeding (n = 19), and portal hypertensive gastropathy (n = 3). Portal vein stent or stent graft was placed via the transhepatic route to relieve the portal hypertension-related symptoms. Clinical success was defined as the resolution of portal hypertension-related symptoms. Clinical success, stent patency, recurrence of symptoms, overall survival, and procedure-related adverse events were compared between stent placement and stent graft placement groups.
Results:
Clinical success rate was higher in the stent graft group (12/13, 92.3%) than that in the stent group (29/45, 64.4%) (p = 0.052). After the initial relief of portal hypertension-related symptoms, a larger proportion of patients suffered the recurrence of symptoms in the stent group (18/29, 62.1%) than in the stent graft group (4/12, 33.3%) (p = 0.093). While the overall survival was not significantly different between the two groups (13 months in the stent graft group vs. 13 months in the stent group), longer patency was observed in the stent graft group (13 months) than in the stent group (10 months) (p =.0.018). The procedure-related adverse events were not observed in both groups.
Conclusion:
The stent graft placement for the malignant portal vein occlusion may provide more immediate symptom relief and longer patency compared to those in the stent placement without the expense of patient safety.